MX2009013215A - Compuestos y composiciones como inhibidores de itpkb. - Google Patents

Compuestos y composiciones como inhibidores de itpkb.

Info

Publication number
MX2009013215A
MX2009013215A MX2009013215A MX2009013215A MX2009013215A MX 2009013215 A MX2009013215 A MX 2009013215A MX 2009013215 A MX2009013215 A MX 2009013215A MX 2009013215 A MX2009013215 A MX 2009013215A MX 2009013215 A MX2009013215 A MX 2009013215A
Authority
MX
Mexico
Prior art keywords
compounds
compositions
itpkb
inhibitors
itpkb inhibitors
Prior art date
Application number
MX2009013215A
Other languages
English (en)
Inventor
Xia Wang
Jiqing Jiang
Donald S Karanewsky
Badry Bursulaya
Yi Liu
Shifeng Pan
Yun Feng Xie
Dai Cheng
Yang Yang
Yongqin Wan
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of MX2009013215A publication Critical patent/MX2009013215A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings

Abstract

La invención proporciona una nueva clase de compuestos de fórmula (I), composiciones farmacéuticas que comprenden tales compuestos y métodos para usar tales compuestos para tratar o prevenir enfermedades o trastornos asociados con actividades anormales o no reguladas de la célula B, particularmente enfermedades o trastornos que involucran la activación anormal de 3-cinasa B de 1,4,5-trisfosfato de inositol (ITPKb).
MX2009013215A 2007-06-15 2008-06-12 Compuestos y composiciones como inhibidores de itpkb. MX2009013215A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94435407P 2007-06-15 2007-06-15
PCT/US2008/066664 WO2008157210A1 (en) 2007-06-15 2008-06-12 Compounds and compositions as itpkb inhibitors

Publications (1)

Publication Number Publication Date
MX2009013215A true MX2009013215A (es) 2010-01-25

Family

ID=39673403

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013215A MX2009013215A (es) 2007-06-15 2008-06-12 Compuestos y composiciones como inhibidores de itpkb.

Country Status (16)

Country Link
US (2) US8178526B2 (es)
EP (1) EP2167498B1 (es)
JP (1) JP2010529993A (es)
KR (1) KR20100020997A (es)
CN (1) CN101743243A (es)
AT (1) ATE481400T1 (es)
AU (1) AU2008266185B2 (es)
BR (1) BRPI0813929A2 (es)
CA (1) CA2688487A1 (es)
DE (1) DE602008002600D1 (es)
EA (1) EA200901656A1 (es)
ES (1) ES2351545T3 (es)
MX (1) MX2009013215A (es)
PL (1) PL2167498T3 (es)
PT (1) PT2167498E (es)
WO (1) WO2008157210A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110263610A1 (en) * 2008-04-04 2011-10-27 Irm Llc Compounds and compositions as itpkb inhibitors
CN108689876B (zh) * 2018-06-28 2020-11-27 苏州东南药业股份有限公司 一种8-(2-羟基苯甲酰胺基)辛酸钠的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
RU2130453C1 (ru) 1992-12-17 1999-05-20 Пфайзер Инк. Замещенные пиразолы, фармацевтическая композиция на их основе, способ лечения, промежуточный продукт
DE69615376T2 (de) * 1995-07-13 2002-09-05 Knoll Gmbh Piperazin-derivate als heilmittel
US6727264B1 (en) * 2001-07-05 2004-04-27 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as MCH selective antagonists
GB0228417D0 (en) * 2002-12-05 2003-01-08 Cancer Rec Tech Ltd Pyrazole compounds
WO2004066926A2 (en) * 2003-01-25 2004-08-12 Irm Llc Methods and compositions for modulating t lymphocytes
JP4728962B2 (ja) * 2003-05-19 2011-07-20 アイアールエム・リミテッド・ライアビリティ・カンパニー 免疫抑制化合物および組成物
WO2005019182A1 (en) 2003-08-20 2005-03-03 Bayer Healthcare Ag Pyrazolylmethylbenzamide derivatives as p2xt-receptor antagonists
JP2007507540A (ja) * 2003-10-02 2007-03-29 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
US20080188483A1 (en) * 2005-03-15 2008-08-07 Irm Llc Compounds and Compositions as Protein Kinase Inhibitors
BRPI0714440A2 (pt) * 2006-07-21 2013-04-24 Irm Llc composto inibidor de itpkb, uso do mesmo e composiÇço farmacÊutica

Also Published As

Publication number Publication date
US20120202782A1 (en) 2012-08-09
DE602008002600D1 (de) 2010-10-28
JP2010529993A (ja) 2010-09-02
BRPI0813929A2 (pt) 2017-05-09
WO2008157210A1 (en) 2008-12-24
AU2008266185A1 (en) 2008-12-24
EA200901656A1 (ru) 2010-06-30
PT2167498E (pt) 2010-11-29
EP2167498B1 (en) 2010-09-15
KR20100020997A (ko) 2010-02-23
AU2008266185B2 (en) 2011-12-08
EP2167498A1 (en) 2010-03-31
CA2688487A1 (en) 2008-12-24
PL2167498T3 (pl) 2011-03-31
ES2351545T3 (es) 2011-02-07
CN101743243A (zh) 2010-06-16
US8178526B2 (en) 2012-05-15
US20100184748A1 (en) 2010-07-22
ATE481400T1 (de) 2010-10-15

Similar Documents

Publication Publication Date Title
WO2008011611A3 (en) Compounds and compositions as itpkb inhibitors
MX2010010877A (es) Compuestos y composiciones como inhibidores de itpkb.
TN2012000081A1 (en) Compounds and compositions as protein kinase inhibitors
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
MX2009004716A (es) Compuestos y composiciones en la forma de inhibidores de quinasa de proteina.
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
GEP20146125B (en) Aminopyrimidines as syk inhibitors
MX2010009207A (es) Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
TW200726753A (en) 2,4-diamino-pyrimidines as aurora inhibitors
GEP20146197B (en) New compounds
MX2012002366A (es) Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
MX2009006540A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides.
GEP20135724B (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
MX2010009837A (es) Tiazolil-dihidro-indazoles.
WO2011159124A3 (ko) Ｉｎｔｅｒｌｅｕｋｉｎ-６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
AU2011279845A8 (en) Novel pyrrolidine derived beta 3 adrenergic receptor agonists
MY152685A (en) Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments
MX2009013215A (es) Compuestos y composiciones como inhibidores de itpkb.
MY152040A (en) Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration